Clinical Trial Update: HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) [Phase 2]

View source ↗

Summary

A Phase 2 trial (TASK-03) evaluating hepatic arterial infusion chemotherapy combined with sintilimab and a bevacizumab biosimilar in advanced hepatocellular car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Hepatic artery infusion chemotherapy (HAIC) (hepatic arterial infusion chemotherapy)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING